Outlook Therapeutics reports a Q3 non-GAAP EPS of -$0.09 and revenue of $9K, missing estimates by $0.02 and $0.96M respectively.
Outlook Therapeutics reported a third-quarter non-GAAP loss per share of -$0.09, missing estimates by $0.02. Revenue fell sharply to $9K, down from $1.51M year-over-year and $0.96M below expectations.
The company’s cash position stood at $11.2 million as of June 30, 2026, excluding proceeds from a recent public offering. The steep revenue decline reflects ongoing challenges in its operational performance.
No immediate market reaction was disclosed in the release.